TY - JOUR T1 - Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases JF - Anticancer Research JO - Anticancer Res SP - 923 LP - 931 DO - 10.21873/anticanres.13195 VL - 39 IS - 2 AU - KOICHI SARUWATARI AU - TOKUNORI IKEDA AU - SHO SAEKI AU - NAOKI SHINGU AU - KOSUKE IMAMURA AU - TAIYOU KOMATU AU - SUNAO USHIJIMA AU - HIROTAKA MARUYAMA AU - KOSUKE KASHIWABARA AU - YUSUKE TOMITA AU - HIDENORI ICHIYASU AU - KAZUHIKO FUJII AU - TAKURO SAKAGAMI Y1 - 2019/02/01 UR - http://ar.iiarjournals.org/content/39/2/923.abstract N2 - Background/Aim: The optimal treatment strategy for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) has not yet been fully determined. The aim of this study was to investigate the optimal management of EGFR-mutant NSCLC patients with BM. Patients and Methods: A multicenter retrospective study was performed on the clinical outcomes of 81 advanced/recurrent EGFR-mutant NSCLC patients with BM treated with EGFR–tyrosine kinase inhibitors (EGFR-TKIs) (gefitinib n=52 or erlotinib n=29). Results: Among the 81 patients, 30 patients received upfront cranial radiotherapy (CRT) and 51 did not. The multivariate cox analyses revealed that the use of erlotinib and upfront CRT were independent predictive factors for overall survival (OS) (erlotinib: HR 0.21; 95% CI, 0.10-0.48; p<0.001; upfront CRT: HR 0.42; 95% CI, 0.20-0.88; p=0.022). Conclusion: Erlotinib and upfront CRT were associated with a favorable prognosis among EGFR-mutant NSCLC patients with BM. Upfront CRT followed by erlotinib may be an appropriate initial management approach for EGFR-mutant NSCLC patients with BM. ER -